Tech Company Financing Transactions
Amphix Bio Funding Round
Private investors participated in a $12.5 million Seed venture round for Amphix Bio. The round was announced on 12/18/2025.
Transaction Overview
Company Name
Announced On
12/18/2025
Transaction Type
Debt
Amount
$12,500,000
Round
Seed
Investors
Proceeds Purpose
The funding will allow the company to advance toward clinical trials following recent regulatory milestones for two products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 North Aberdeen Street 900
Chicago, IL 60642
US
Chicago, IL 60642
US
Phone
Undisclosed
Website
Email Address
Overview
Amphix Bio spun out from Northwestern University in Chicago, IL in 2021. The company is developing a new platform technology, Supramolecular Therapeutic Peptides (STPs), that modifies immunological response and initiates regenerative processes to restore function lost from injury, disease, or aging. These therapies trigger targeted signaling pathways while forming scaffolds to support biological repair. Amphix Bio's goal is to increase human healthspan -- the length of time that people can live productive, fulfilling lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nick Sather
Chief Scientific Officer
Samuel Stupp
VP - Operations
Hussain Sangji
Browse more venture capital transactions:
Prev: 12/18/2025: Tebra venture capital transaction
Next: 12/18/2025: Edison Scientific venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs